載入中
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
收盤時
US$7.46
+US$0.08 · +1.08%
盤後
US$7.54
+US$0.08 · +1.07%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日內區間
目前US$7.46
52週區間
目前US$7.46
盤中時間採用ET。市場資料可能有所延遲。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日內區間
目前US$7.46
52週區間
目前US$7.46
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.50
上漲空間 94.37%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年3月26日 | 1:5 | — | — |
已生效 2019年3月26日
1:5
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1840.1萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Avantis U.S. Small Cap Value ETFAVUV1674.31萬0.05%308.51億 USD0.25%US$119.94+0.25%
iShares Russell 2000 ETFIWM1450.53萬0.02%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF697.56萬0.01%954億 USD0.05%US$233.52-0.63%
State Street SPDR S&P Pharmaceuticals ETFXPH558.86萬1.21%4.69億 USD0.35%US$64.01-0.99%
Pacer US Small Cap Cash Cows ETFCALF489.28萬0.14%35.87億 USD0.59%US$54.76+0.18%
Vanguard Russell 2000 ETFVTWO353.95萬0.02%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA254.56萬0.01%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIAvantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
